NCT05271669

Brief Summary

The risk of household spread of SARS-CoV-2 hinges on both the transmission dynamics of the virus circulating in the community as well as the seroprotection pattern of constituent members, which can be attributed to vaccination and previous infections. This study is conceptualised to assess the dynamicity of SARS-CoV-2 risk at the household level, through monitoring the pattern of seroprotection, in conjunction with the vaccination coverage, history of infection and exposure risk in the setting of Hong Kong.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,350

participants targeted

Target at P75+ for all trials

Timeline
8mo left

Started Jun 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Jun 2022Jan 2027

First Submitted

Initial submission to the registry

March 7, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 9, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

June 6, 2022

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Last Updated

March 18, 2026

Status Verified

March 1, 2026

Enrollment Period

4.1 years

First QC Date

March 7, 2022

Last Update Submit

March 16, 2026

Conditions

COVID-19

Keywords

serologycohort studySARS-CoV-2 antibody

Outcome Measures

Primary Outcomes (2)

  • Proportion of participants with COVID-19 protective immunity

    Prevalence of SARS-CoV-2 spike antibody

    1 year

  • Proportion of participants with marker of past COVID-19 infection

    Prevalence of SARS-CoV-2 nucleocapsid antibody

    1 year

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults of households enrolling in a population cohort covering residents from all 18 districts in Hong Kong.

You may qualify if:

  • adults of age 18 or above, or children under the age of 18 with informed consent of the legal guardian
  • normally residing in Hong Kong
  • could communicate in spoken and written Chinese and/or English

You may not qualify if:

  • individuals with mental illness
  • prisoners

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shui Shan Lee

Hong Kong, HONG KONG, 0000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples for serology testing

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Professor

Study Record Dates

First Submitted

March 7, 2022

First Posted

March 9, 2022

Study Start

June 6, 2022

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

January 1, 2027

Last Updated

March 18, 2026

Record last verified: 2026-03

Locations

CN(1)